Your search returned 2 results.

Results
	1.	Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. [electronic resource] by Belani, Chandra P Nemunaitis, John J Chachoua, Abraham Eisenberg, Peter D Raez, Luiz E Cuevas, J Daniel Mather, Cecile B Benner, Rebecca J Meech, Sandra J Producer: 20140501 In: Cancer biology & therapy vol. 14 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. [electronic resource] by Ramalingam, Suresh S Jänne, Pasi A Mok, Tony O'Byrne, Kenneth Boyer, Michael J Von Pawel, Joachim Pluzanski, Adam Shtivelband, Mikhail Docampo, Lara Iglesias Bennouna, Jaafar Zhang, Hui Liang, Jane Q Doherty, Jim P Taylor, Ian Mather, Cecile B Goldberg, Zelanna O'Connell, Joseph Paz-Ares, Luis Producer: 20150223 In: The Lancet. Oncology vol. 15 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search